Longeveron Inc. Appoints New CFO Nirav S. Jhaveri

What Happened Longeveron Inc. announced the appointment of Nirav S. Jhaveri as Chief Financial Officer, principal financial officer and principal accounting officer, effective August 17, 2026. Mr. Jhaveri, age 48, brings over 25 years of biopharma and biotech finance leadership, including recent CFO roles at Opus Genetics (Feb 2024–Jun 2025) and prior senior finance roles at Insilico Medicine and Journey Medical. Marie Washburn will remain with the company as Vice President and Corporate Controller.

Key Details

• Effective date: August 17, 2026.
• Base salary: $400,000 per year.
• Annual cash incentive: target equal to 45% of base salary.
• Equity: grant of 300,000 Restricted Stock Units (RSUs), vesting quarterly over three years.
• Other: eligible for standard employee benefits and termination/severance benefits; Letter Agreement filed as Exhibit 10.1 to the 8‑K.

Why It Matters A new CFO can affect Longeveron’s financial leadership, reporting and interactions with capital markets and investors. The compensation package ties a significant portion of pay to performance and equity (RSUs), aligning the new CFO’s incentives with shareholder interests. Investors should note the change in financial leadership and the potential for continuity given the company’s existing controller remains in place.